Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks-Reference-Cited by-同舟云学术

Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks

Published:2023-06-01 Issue:11 Volume:207 Page:1539-1542
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Birring Surinder S.¹^ORCID,Dicpinigaitis Peter V.²,Smith Jaclyn A.³^ORCID,Morice Alyn H.⁴^ORCID,McGarvey Lorcan P.⁵,Pavord Ian D.⁶,Nguyen Allison Martin⁷^ORCID,Schelfhout Jonathan⁷,Li Qing⁷,Iskold Beata⁷,Green Stuart A.⁷,Philip George⁷^ORCID,Muccino David R.⁷,La Rosa Carmen⁷

Affiliation:

1. Centre for Human & Applied Physiological Sciences, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King’s College London, London, United Kingdom;

2. Albert Einstein College of Medicine & Montefiore Medical Center, Bronx, New York;

3. Division of Immunology, Immunity to Infection & Respiratory Medicine, University of Manchester and Manchester University National Health Service Trust, Manchester, United Kingdom;

4. Hull York Medical School, Cottingham, United Kingdom;

5. Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Belfast, Northern Ireland;

6. Oxford National Institute for Health Research Respiratory Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; and

7. Merck & Co., Inc., Rahway, New Jersey

Funder

Merck Sharp & Dohme LLC

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Link

https://www.atsjournals.org/doi/pdf/10.1164/rccm.202211-2128LE

Reference9 articles.

1. Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials

2. Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough